Diagnosis and management of critical illness polyneuropathy and critical illness myopathy

Current Treatment Options in Neurology

Volumn 9, Issue 2, 2007, Pages 85-92

  Bird, Shawn J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CORTICOSTEROID; GLUTAMINE; IMMUNOGLOBULIN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTIFICIAL VENTILATION; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG MEGADOSE; FEASIBILITY STUDY; HUMAN; INSULIN TREATMENT; INTENSIVE CARE UNIT; MEDICAL CARE; MOTOR NEUROPATHY; MUSCLE WEAKNESS; MYOPATHY; NEUROMUSCULAR BLOCKING; PASSIVE IMMUNIZATION; PHYSIOTHERAPY; POLYNEUROPATHY; REVIEW; RISK FACTOR; SENSORY NEUROPATHY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33847649472     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-007-0034-1     Document Type: Review

References (45)

1. Witt NJ, Zochodne DW, Bolton CF, et al.: Peripheral nerve function in sepsis and multiple organ failure. Chest 1991, 99:176-184.
2. Leijten FS, Harinck-de Weerd JE, Poortvleit DC, de Weerd AW: The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995, 274:1221-1225.
3. Lacomis D, Petrella JT, Giuliani MJ: Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998, 21:610-617.
4. De Letter MC, Schmitz PI, Visser LH, et al.: Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001, 29:2281-2286.
5. De Jonghe B, Sharshar T, Lefaucher JP, et al.: Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002, 288:2859-2867.
6. Bednarik J, Vondracek P, Dusek L, et al.: Risk factors for critical illness polyneuromyopathy. J Neurol 2005, 252:343-351.
7. Bolton CF: Electrophysiologic studies of critically ill patients. Muscle Nerve 1987, 10:129-135.
8. Bolton CF, Young GB, Zochodne DW: The neurologic complications of sepsis. Ann Neurol 1993, 33:94-100.
9. Zochodne DW, Bolton CF, Wells GA, et al.: Critical illness polyneuropathy. Brain 1987, 110:819-842.
10. Zifko U, Zipko H, Bolton CF: Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci 1998, 159:186-198.
11. Bird SJ, Rich MM: Critical illness myopathy and polyneuropathy. Curr Neurol Neurosci Rep 2002, 2:527-533.
12. Bolton CF: Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996, 24:1408-1416.
13. Op de Coul AAW, Lambregts PC, Koeman J, et al.: Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg 1985, 87:17-22.
14. Hirano M, Ott BR, Raps EC, et al.: Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992, 42:2082-2087.
15. Hanson P, Dive A, Brucher JM, et al.: Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20:1371-1380.
16. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ: Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996, 40:645-654.
17. Rich MM, Teener JW, Raps EC, et al.: Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996, 46:731-736.
18. Rich MM, Bird SJ, Raps EC, et al.: Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997, 20:665-673.
19. Trojaborg W, Weimer LH, Hays AP: Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy--a reappraisal. Clin Neurophysiol 2001, 112:1586-1593.
20. Bednarik J, Lukas Z, Vondracek P: Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Intensive Care Med 2003, 29:1505-1514.
21. Lefaucher JP, Nordine T, Rodriguez P, Brouchard L: Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 2006, 77:500-506.
22. Danon MJ, Carpenter S: Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve 1991, 14:1131-1139.
23. Teener JW, Rich MM: Dysregulation of sodium channel gating in critical illness myopathy. J Muscle Res Cell Motil 2006, 27:291-296.
24. Berek K, Margreiter J, Willeit J: Polyneuropathies in critically ill patients: a prospective evaluation. Intensive Care Med 1993, 22:849-855.
25. Leijten FSS, Harinck-De Weerd JE, Poortvliet DCJ, De Weerd AW: Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996, 22:856-861.
26. Lacomis D, Zochodne DW, Bird SJ: Critical illness myopathy: what's in a name? Muscle Nerve 2000, 23:1767-1772.
27. Campellone JV, Lacomis D, Kramer DJ, et al.: Acute myopathy after liver transplantation. Neurology 1998, 50:46-53.
28. Hanson P, Dive A, Brucher JM, et al.: Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20:1371-1380.
29. De Jonghe B, Bastuji-Garin S, Sharshar T, et al.: Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med 2004, 30:1117-1121.
30. Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL, et al.: Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 2005, 33:349-354.
31. David WS, Roehr CL, Leatherman JW: EMG findings in acute myopathy with status asthmaticus, steroids, and paralytics: clinical and electrophysiologic correlation. Electromyogr Clin Neurophysiol 1998, 38:371-376.
32. Bolton CF: Neuromuscular manifestations of critical illness. Muscle Nerve 2005, 32:140-163.
33. Latronico N, Shehu I, Seghelini E: Neuromuscular sequelae of critical illness. Curr Opin Crit Care 2005, 11:381-390.
34. Fletcher SN, Kennedy DD, Ghosh IR, et al.: Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003, 31:1012-1016.
35. Hansen-Flaschen JH, Cowen J, Raps EC: Neuromuscular blockade in the intensive care unit: more than we bargained for. Am Rev Respir Dis 1993, 147:234-236.
36. Sladen RN: Neuromuscular blocking agents in the intensive care unit: a two-edged sword. Crit Care Med 1995, 23:423-428.
37. Murray MJ, Cowen J, DeBlock H, et al.: Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002, 30:142-156.
38. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006, 354:1671-1684.
39. Wijdicks EF, Fulgham JR: Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 1994, 17:1494-1495.
40. Mohr M, Englisch L, Roth A, et al.: Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997, 23:1144-1149.
41. Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359-1367.
42. Van den Berghe G, Schoonheydt K, Becx P, et al.: Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005, 64:1348-1353.
43. Van der Schaaf M, Beelen A, De Vos R: Functional outcome in patients with critical illness polyneuropathy. Disabil Rehabil 2004, 26:1189-1197.
44. Novak F, Heyland DK, Avenell A, et al.: Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med 2002, 30:2022-2029.
45. Friedrich O: Critical illness myopathy: what is happening? Curr Opin Clin Nutr Metab Care 2006, 9:403-409.